379 related articles for article (PubMed ID: 12851783)
1. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Van Cutsem E; Pozzo C; Starkhammar H; Dirix L; Terzoli E; Cognetti F; Humblet Y; Garufi C; Filez L; Gruia G; Cote C; Barone C
Ann Oncol; 1998 Nov; 9(11):1199-204. PubMed ID: 9862050
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Lavrenkov K; Man S; Mermershtain W; Cohen Y
J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
Rosati G; Rossi A; Reggiardo G; Manzione L
Oncology; 2002; 62(3):209-15. PubMed ID: 12065867
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Graeven U; Ridwelski K; Artandi M; Espana P; Schölmerich J; Rosales AM; Carlsson G; Borner M; Boussard B; Schmiegel W
Oncol Rep; 2005 Apr; 13(4):681-8. PubMed ID: 15756442
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Comella P; Massidda B; Natale D; Putzu C; Sandomenico C; Filippelli G; Palmeri S; Condemi G; Vessia G; Barberis G; Ionta MT; Tafuto S; Barbato E
Clin Colorectal Cancer; 2011 Mar; 10(1):42-7. PubMed ID: 21609935
[TBL] [Abstract][Full Text] [Related]
12. Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study.
Bonetti A; Zaninelli M; Durante E; Fraccon AP; Franceschi T; Pasini F; Zustovich F; Brienza S
Tumori; 2006; 92(5):389-95. PubMed ID: 17168430
[TBL] [Abstract][Full Text] [Related]
13. [Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
Nakamura T; Kurachi K; Fukazawa A; Hayashi T; Nakamura K; Nakajima A; Suzuki S; Konno H
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1697-701. PubMed ID: 18931571
[TBL] [Abstract][Full Text] [Related]
14. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V
Oncology; 2005; 69(5):384-90. PubMed ID: 16319509
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer.
Recchia F; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Rea S
Anticancer Res; 2003; 23(3C):2903-8. PubMed ID: 12926132
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Goldberg RM; Erlichman C
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093
[TBL] [Abstract][Full Text] [Related]
18. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
[TBL] [Abstract][Full Text] [Related]
20. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
